Aerie Pharmaceuticals reports positive results from AR-13324 study Aerie Pharmaceuticals announced the results of preclinical in vivo research demonstrating the ability of AR-13324 to reduce episcleral venous pressure, or EVP, in the eye. AR-13324 previously has been shown to lower intraocular pressure, or IOP, by increasing fluid outflow through the trabecular pathway, the eye's primary drain, and by reducing the production of fluid in the eye. The present study affirmed the hypothesis that AR-13324 also can lower IOP through a third mechanism of action, the reduction of EVP. This may represent a breakthrough in the lowering of IOP in patients with glaucoma and ocular hypertension.
News For AERI From The Last 14 Days
Check below for free stories on AERI the last two weeks.